Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hoth Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical issuer’s material events, capital structure actions, governance arrangements and listing compliance matters. Recent 8-K disclosures cover registered direct offerings of common stock, private-placement warrants, use of a Form S-3 shelf registration, and at-the-market offering prospectus supplements.
The filing record also includes Regulation FD and other-event disclosures for management presentation materials about the therapeutics pipeline and weight-loss drug program, executive employment agreement information, Nasdaq minimum bid price compliance notices, and the formation of Rocket One Inc., a wholly owned subsidiary formed to acquire, own and operate space-industry assets, including nano rocket systems for nanosatellite deployment.
Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.
Key points from the filing:
- The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
- The company maintains discretion to update the materials but has no obligation to do so
- Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
- The information will not be incorporated by reference into any Securities Act or Exchange Act filings
The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.